{"id":"d5cb5c465f2c","type":"article","url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","title":"Biomarkers bij HF met centrale slaapapneu: SERVE-HF","title_en":"Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.12521","source_url":"https://doi.org/10.1002/ehf2.12521","authors":["João Pedro Ferreira","Kévin Duarte","Holger Woehrle","Martin R Cowie","Karl Wegscheider","Christiane Angermann","Marie-Pia d'Ortho","Erland Erdmann","Patrick Levy","Anita K Simonds","Virend K Somers","Helmut Teschler","Patrick Rossignol","Wolfgang Koenig","Faiez Zannad"],"significance":5,"published":"2020-04-01","source_date":"2020-04-01","image":"","kennis":[],"congress":"","summary_en":"This SERVE-HF biomarker analysis characterized biomarker profiles in heart failure patients with central sleep apnea, exploring whether circulating markers identify patients at risk from adaptive servo-ventilation therapy.","created":"2026-07-03T10:28:29Z","updated":"2026-07-03T13:27:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"SERVE-HF subanalyse naar biomarkers bij hartfalenpatiënten met centrale slaapapneu.","abstract_original":"AIMS: The Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients with Heart Failure trial investigated the effects of adaptive servo-ventilation (ASV) (vs. control) on outcomes of 1325 patients with heart failure and reduced ejection fraction (HFrEF) and central sleep apnoea (CSA). The primary outcome (a composite of all-cause death or unplanned HF hospitalization) did not differ between the two groups. However, all-cause and cardiovascular (CV) mortality were higher in the ASV group. Circulating biomarkers may help in better ascertain patients' risk, and this is the first study applying a large set of circulating biomarkers in patients with both HFrEF and CSA. METHODS AND RESULTS: Circulating protein-biomarkers (n = 276) ontologically involved in CV pathways, were studied in 749 (57% of the trial population) patients (biomarker substudy), to investigate their association with the study outcomes (primary outcome, CV death and all-cause death). The mean age was 69 ± 10 years, and > 90% were male. The groups (ASV vs. control and biomarker substudy vs. no biomarker) were well balanced. The \"best\" clinical prognostic model included male sex, systolic blood pressure < 120 mmHg, diabetes, loop diuretic, cardiac device, 6-min walking test distance, and N-terminal pro BNP as the strongest prognosticators. On top of the \"best\" clinical prognostic model, the biomarkers that significantly improved both the discrimination (c-index) and the net reclassification index (NRI) of the model were soluble suppression of tumorigenicity 2 for the primary outcome; neurogenic locus notch homolog protein 3 (Notch-3) for CV-death and all-cause death; and growth differentiation factor 15 (GDF-15) for all-cause death only. CONCLUSIONS: We studied 276 circulating biomarkers in patients with HFrEF and central sleep apnoea; of these biomarkers, three added significant prognostic information on top of the best clinical model: soluble suppression of tumorigenicity 2 (primary outcome), Notch-3 (CV and all-cause death), and GDF-15 (all-cause death)."}